Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Japanese Patients With COPD
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL
inhalation solution delivered by the Respimat inhaler once daily for 4 weeks in Japanese
patients with chronic obstructive pulmonary disease (COPD). The selection of the optimum
dose(s) will be based on bronchodilator efficacy, safety evaluations and pharmacokinetic
evaluations.